{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:42:59Z","timestamp":1793727779709,"version":"4.6.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Jiangsu Provincial Traditional Chinese Medicine Digestive Medicine Innovation Center","award":["CXZX202208"],"award-info":[{"award-number":["CXZX202208"]}]},{"name":"Construction of high-level key disciplines of Traditional Chinese medicine"},{"name":"the Postgraduate Research & Practice Innovation Program of Jiangsu Province","award":["KYCX22_1938"],"award-info":[{"award-number":["KYCX22_1938"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Qin-Yu-Qing-Chang decoction (QYQC), an herbal formula from China, is extensively employed to manage ulcerative colitis (UC) and exhibits potential benefits for colonic function. Nevertheless, the fundamental molecular mechanisms of QYQC remain largely uncharted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The primary constituents of QYQC were determined utilizing UHPLC-MS\/MS analysis and the effectiveness of QYQC was assessed in a mouse model of colitis induced by dextran sulfate sodium. Evaluations of colon inflammatory responses and mucosal barrier function were thoroughly assessed. RNA sequencing, molecular docking, colonic energy metabolism, and 16S rRNA sequencing analysis were applied to uncover the complex mechanisms of QYQC in treating UC. Detect the signal transduction of the peroxisome proliferator-activated receptor-\u03b3 (PPAR-\u03b3) both in the nucleus and cytoplasm. Furthermore, a PPAR-\u03b3 antagonist was strategically utilized to confirm the functional targets that QYQC exerts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Utilizing UHPLC-MS\/MS, the principal constituents of the nine traditional Chinese medicinal herbs comprising QYQC were systematically identified. QYQC treatment substantially ameliorated colitis in mice, as evidenced by the improvement in symptoms and the reduction in colonic pathological injuries. Besides, QYQC treatment mitigated the inflammatory response and improved mucosal barrier function. Furthermore, QYQC enhanced the mitochondria citrate cycle (TCA cycle) by triggering PPAR-\u03b3 signaling and increasing the proportion of PPAR-\u03b3 entering the nucleus. This prevented the unconstrained expansion of facultative anaerobes, particularly pathogenic\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      (\n                      <jats:italic>E. coli<\/jats:italic>\n                      , family\n                      <jats:italic>Enterobacteriaceae<\/jats:italic>\n                      ) and thus improved colitis. Results of molecular docking indicated that the representative chemical components of QYQC including Baicalin, Paeoniflorin, Mollugin, and Imperatorin bound well with PPAR-\u03b3. The impact of QYQC on colitis was diminished in the presence of a PPAR-\u03b3 antagonist.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In summary, QYQC ameliorates UC by activating PPAR-\u03b3 signaling and increasing the proportion of PPAR-\u03b3 entering the nucleus, which enhances the energy metabolism of intestinal epithelial cells and thereby preventing the uncontrolled proliferation of facultative anaerobes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-024-01006-9","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T03:02:23Z","timestamp":1727319743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Qin-Yu-Qing-Chang decoction reshapes colonic metabolism by activating PPAR-\u03b3 signaling to inhibit facultative anaerobes against DSS-induced colitis"],"prefix":"10.1186","volume":"19","author":[{"given":"Feng","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiheng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuguang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulai","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"1006_CR1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","volume":"6","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6:74.","journal-title":"Nat Rev Dis Primers"},{"key":"1006_CR2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S2468-1253(21)00014-5","volume":"6","author":"B Barberio","year":"2021","unstructured":"Barberio B, Zamani M, Black CJ, Savarino EV, Ford AC. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:359\u201370.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1006_CR3","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1016\/j.cgh.2020.08.053","volume":"19","author":"LA Shafer","year":"2021","unstructured":"Shafer LA, Sofia MA, Rubin DT, Steinhart AH, Ng SC, Reches L, et al. An international multicenter comparison of IBD-related disability and validation of the IBDDI. Clin Gastroenterol Hepatol. 2021;19:2524\u201331.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1006_CR4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2468-1253(21)00065-0","volume":"6","author":"D Alsoud","year":"2021","unstructured":"Alsoud D, Verstockt B, Fiocchi C, Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol. 2021;6:589\u201395.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1006_CR5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13073-014-0107-1","volume":"6","author":"D Knights","year":"2014","unstructured":"Knights D, Silverberg MS, Weersma RK, Gevers D, Dijkstra G, Huang H, et al. Complex host genetics influence the microbiome in inflammatory bowel disease. Genome Med. 2014;6:107.","journal-title":"Genome Med"},{"key":"1006_CR6","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","volume":"569","author":"J Lloyd-Price","year":"2019","unstructured":"Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569:655\u201362.","journal-title":"Nature"},{"key":"1006_CR7","first-page":"46","volume":"30","author":"A Cardoneanu","year":"2021","unstructured":"Cardoneanu A, Mihai C, Rezus E, Burlui A, Popa I, Cijevschi PC. Gut microbiota changes in inflammatory bowel diseases and ankylosing spondilytis. J Gastrointest Liver. 2021;30:46\u201354.","journal-title":"J Gastrointest Liver"},{"key":"1006_CR8","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.cell.2019.07.045","volume":"178","author":"DR Plichta","year":"2019","unstructured":"Plichta DR, Graham DB, Subramanian S, Xavier RJ. Therapeutic opportunities in inflammatory bowel disease: mechanistic dissection of host-microbiome relationships. Cell. 2019;178:1041\u201356.","journal-title":"Cell"},{"key":"1006_CR9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.freeradbiomed.2016.09.022","volume":"105","author":"F Rivera-Ch\u00e1vez","year":"2017","unstructured":"Rivera-Ch\u00e1vez F, Lopez CA, B\u00e4umler AJ. Oxygen as a driver of gut dysbiosis. Free Radical Biol Med. 2017;105:93\u2013101.","journal-title":"Free Radical Biol Med"},{"key":"1006_CR10","doi-asserted-by":"crossref","unstructured":"Caioni G, Viscido A, d\u2019Angelo M, Panella G, Castelli V, Merola C, et al. Inflammatory bowel disease: new insights into the interplay between environmental factors and PPAR\u03b3. Int J Mol Sci. 2021;22(3):985.","DOI":"10.3390\/ijms22030985"},{"key":"1006_CR11","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/ibd\/izaa273","volume":"27","author":"J Fang","year":"2021","unstructured":"Fang J, Wang H, Xue Z, Cheng Y, Zhang X. PPAR\u03b3: the central mucus barrier coordinator in ulcerative colitis. Inflammatory Bowel Dis. 2021;27:732\u201341.","journal-title":"Inflammatory Bowel Dis"},{"key":"1006_CR12","volume":"186","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhang J, Duan L. The role of microbiota-mitochondria crosstalk in pathogenesis and therapy of intestinal diseases. Pharmacol Res. 2022;186: 106530.","journal-title":"Pharmacol Res"},{"key":"1006_CR13","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.aam9949","volume":"357","author":"MX Byndloss","year":"2017","unstructured":"Byndloss MX, Olsan EE, Rivera-Ch\u00e1vez F, Tiffany CR, Cevallos SA, Lokken KL, et al. Microbiota-activated PPAR-\u03b3 signaling inhibits dysbiotic Enterobacteriaceae expansion. Science. 2017;357:570\u20135.","journal-title":"Science"},{"key":"1006_CR14","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.molimm.2004.12.009","volume":"42","author":"MB Crosby","year":"2005","unstructured":"Crosby MB, Svenson J, Gilkeson GS, Nowling TK. A novel PPAR response element in the murine iNOS promoter. Mol Immunol. 2005;42:1303\u201310.","journal-title":"Mol Immunol"},{"key":"1006_CR15","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/gutjnl-2014-307618","volume":"64","author":"G Bouguen","year":"2015","unstructured":"Bouguen G, Langlois A, Djouina M, Branche J, Koriche D, Dewaeles E, et al. Intestinal steroidogenesis controls PPAR\u03b3 expression in the colon and is impaired during ulcerative colitis. Gut. 2015;64:901\u201310.","journal-title":"Gut"},{"key":"1006_CR16","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3892\/ol.2015.3397","volume":"10","author":"X Dou","year":"2015","unstructured":"Dou X, Xiao J, Jin Z, Zheng P. Peroxisome proliferator-activated receptor-\u03b3 is downregulated in ulcerative colitis and is involved in experimental colitis-associated neoplasia. Oncol Lett. 2015;10:1259\u201366.","journal-title":"Oncol Lett"},{"key":"1006_CR17","doi-asserted-by":"crossref","first-page":"13133","DOI":"10.1021\/acs.jafc.8b03942","volume":"66","author":"H Cao","year":"2018","unstructured":"Cao H, Liu J, Shen P, Cai J, Han Y, Zhu K, et al. Protective effect of naringin on DSS-induced ulcerative colitis in mice. J Agric Food Chem. 2018;66:13133\u201340.","journal-title":"J Agric Food Chem"},{"issue":"1","key":"1006_CR18","doi-asserted-by":"crossref","first-page":"e03227","DOI":"10.1128\/mBio.03227-20","volume":"12","author":"SA Cevallos","year":"2021","unstructured":"Cevallos SA, Lee JY, Velazquez EM, Foegeding NJ, Shelton CD, Tiffany CR, et al. 5-aminosalicylic acid ameliorates colitis and checks dysbiotic escherichia coli expansion by activating PPAR-\u03b3 signaling in the intestinal epithelium. MBio. 2021;12(1):e03227.","journal-title":"MBio"},{"key":"1006_CR19","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111580","volume":"139","author":"H Shen","year":"2021","unstructured":"Shen H, Zhang S, Zhao W, Ren S, Ke X, Gu Q, et al. Randomised clinical trial: Efficacy and safety of Qing-Chang-Hua-Shi granules in a multicenter, randomized, and double-blind clinical trial of patients with moderately active ulcerative colitis. Biomed Pharmacother. 2021;139: 111580.","journal-title":"Biomed Pharmacother"},{"key":"1006_CR20","volume":"266","author":"J Hu","year":"2021","unstructured":"Hu J, Huang H, Che Y, Ding C, Zhang L, Wang Y, et al. Qingchang Huashi formula attenuates DSS-induced colitis in mice by restoring gut microbiota-metabolism homeostasis and goblet cell function. J Ethnopharmacol. 2021;266: 113394.","journal-title":"J Ethnopharmacol"},{"key":"1006_CR21","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154452","volume":"107","author":"C Cheng","year":"2022","unstructured":"Cheng C, Hu J, Li Y, Ji Y, Lian Z, Au R, et al. Qing-Chang-Hua-Shi granule ameliorates DSS-induced colitis by activating NLRP6 signaling and regulating Th17\/Treg balance. Phytomedicine. 2022;107: 154452.","journal-title":"Phytomedicine"},{"key":"1006_CR22","volume":"154","author":"J Hu","year":"2022","unstructured":"Hu J, Tong Y, Shen Z, Li Y, Cheng C, Au R, et al. Gegen Qinlian decoction ameliorates murine colitis by inhibiting the expansion of Enterobacteriaceae through activating PPAR-\u03b3 signaling. Biomed Pharmacother. 2022;154: 113571.","journal-title":"Biomed Pharmacother"},{"key":"1006_CR23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40168-021-01028-7","volume":"9","author":"D Li","year":"2021","unstructured":"Li D, Feng Y, Tian M, Ji J, Hu X, Chen F. Gut microbiota-derived inosine from dietary barley leaf supplementation attenuates colitis through PPAR\u03b3 signaling activation. Microbiome. 2021;9:83.","journal-title":"Microbiome"},{"key":"1006_CR24","volume":"169","author":"Q Lv","year":"2021","unstructured":"Lv Q, Xing Y, Liu Y, Chen Q, Xu J, Hu L, et al. Didymin switches M1-like toward M2-like macrophage to ameliorate ulcerative colitis via fatty acid oxidation. Pharmacol Res. 2021;169: 105613.","journal-title":"Pharmacol Res"},{"key":"1006_CR25","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/gut.2006.093484","volume":"55","author":"L Dubuquoy","year":"2006","unstructured":"Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut. 2006;55:1341\u20139.","journal-title":"Gut"},{"key":"1006_CR26","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ptr.7677","volume":"37","author":"Y Su","year":"2023","unstructured":"Su Y, Liang J, Zhang M, Zhao M, Xie X, Wang X, et al. Wogonin regulates colonocyte metabolism via PPAR\u03b3 to inhibit Enterobacteriaceae against dextran sulfate sodium-induced colitis in mice. Phytother Res. 2023;37:872\u201384.","journal-title":"Phytother Res"},{"key":"1006_CR27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/1751-2980.12849","volume":"21","author":"XY Guo","year":"2020","unstructured":"Guo XY, Liu XJ, Hao JY. Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment. J Dig Dis. 2020;21:147\u201359.","journal-title":"J Dig Dis"},{"key":"1006_CR28","volume":"74","author":"D Yao","year":"2021","unstructured":"Yao D, Dai W, Dong M, Dai C, Wu S. MUC2 and related bacterial factors: Therapeutic targets for ulcerative colitis. EBioMedicine. 2021;74: 103751.","journal-title":"EBioMedicine"},{"key":"1006_CR29","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S0016-5085(03)00271-3","volume":"124","author":"L Dubuquoy","year":"2003","unstructured":"Dubuquoy L, Jansson EA, Deeb S, Rakotobe S, Karoui M, Colombel JF, et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology. 2003;124:1265\u201376.","journal-title":"Gastroenterology"},{"key":"1006_CR30","volume":"111","author":"N Wang","year":"2022","unstructured":"Wang N, Kong R, Han W, Bao W, Shi Y, Ye L, et al. Honokiol alleviates ulcerative colitis by targeting PPAR-\u03b3-TLR4-NF-\u03baB signaling and suppressing gasdermin-D-mediated pyroptosis in vivo and in vitro. Int Immunopharmacol. 2022;111: 109058.","journal-title":"Int Immunopharmacol"},{"key":"1006_CR31","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2020.00730","volume":"11","author":"J Decara","year":"2020","unstructured":"Decara J, Rivera P, L\u00f3pez-Gambero AJ, Serrano A, Pav\u00f3n FJ, Baixeras E, et al. Peroxisome proliferator-activated receptors: experimental targeting for the treatment of inflammatory bowel diseases. Front Pharmacol. 2020;11:730.","journal-title":"Front Pharmacol"},{"key":"1006_CR32","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1142\/S0192415X22500756","volume":"50","author":"S Zheng","year":"2022","unstructured":"Zheng S, Xue T, Wang B, Guo H, Liu Q. Chinese medicine in the treatment of ulcerative colitis: the mechanisms of signaling pathway regulations. Am J Chin Med. 2022;50:1781\u201398.","journal-title":"Am J Chin Med"},{"key":"1006_CR33","volume":"318","author":"M Wang","year":"2024","unstructured":"Wang M, Fu R, Xu D, Chen Y, Yue S, Zhang S, et al. Traditional Chinese medicine: a promising strategy to regulate the imbalance of bacterial flora, impaired intestinal barrier and immune function attributed to ulcerative colitis through intestinal microecology. J Ethnopharmacol. 2024;318: 116879.","journal-title":"J Ethnopharmacol"},{"key":"1006_CR34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jcmgh.2017.03.007","volume":"4","author":"E Martini","year":"2017","unstructured":"Martini E, Krug SM, Siegmund B, Neurath MF, Becker C. Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol. 2017;4:33\u201346.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"1006_CR35","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1053\/j.gastro.2017.05.056","volume":"153","author":"J Chang","year":"2017","unstructured":"Chang J, Leong RW, Wasinger VC, Ip M, Yang M, Phan TG. Impaired intestinal permeability contributes to ongoing bowel symptoms in patients with inflammatory bowel disease and mucosal healing. Gastroenterology. 2017;153:723-31.e1.","journal-title":"Gastroenterology"},{"key":"1006_CR36","volume":"133","author":"H Wu","year":"2021","unstructured":"Wu H, Chen QY, Wang WZ, Chu S, Liu XX, Liu YJ, et al. Compound sophorae decoction enhances intestinal barrier function of dextran sodium sulfate induced colitis via regulating notch signaling pathway in mice. Biomed Pharmacother. 2021;133: 110937.","journal-title":"Biomed Pharmacother"},{"key":"1006_CR37","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41575-022-00604-y","volume":"19","author":"EJ Villablanca","year":"2022","unstructured":"Villablanca EJ, Selin K, Hedin CRH. Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression? Nat Rev Gastroenterol Hepatol. 2022;19:493\u2013507.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1006_CR38","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.2174\/092986705774462905","volume":"12","author":"R Kostadinova","year":"2005","unstructured":"Kostadinova R, Wahli W, Michalik L. PPARs in diseases: control mechanisms of inflammation. Curr Med Chem. 2005;12:2995\u20133009.","journal-title":"Curr Med Chem"},{"issue":"23","key":"1006_CR39","doi-asserted-by":"crossref","first-page":"17124","DOI":"10.3390\/ijms242317124","volume":"24","author":"MJ S\u00e1nchez-Quintero","year":"2023","unstructured":"S\u00e1nchez-Quintero MJ, Rodr\u00edguez-D\u00edaz C, Rodr\u00edguez-Gonz\u00e1lez FJ, Fern\u00e1ndez-Casta\u00f1er A, Garc\u00eda-Fuentes E, L\u00f3pez-G\u00f3mez C. Role of mitochondria in inflammatory bowel diseases: a systematic review. Int J Mol Sci. 2023;24(23):17124.","journal-title":"Int J Mol Sci"},{"key":"1006_CR40","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00011-011-0340-7","volume":"60","author":"M Ooi","year":"2011","unstructured":"Ooi M, Nishiumi S, Yoshie T, Shiomi Y, Kohashi M, Fukunaga K, et al. GC\/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis. Inflamm Res. 2011;60:831\u201340.","journal-title":"Inflamm Res"},{"key":"1006_CR41","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.isci.2019.10.046","volume":"21","author":"H Qi","year":"2019","unstructured":"Qi H, Gao Y, Li Y, Wei J, Su X, Zhang C, et al. Induction of inflammatory macrophages in the gut and extra-gut tissues by colitis-mediated Escherichia coli. iScience. 2019;21:474\u201389.","journal-title":"iScience"},{"key":"1006_CR42","volume":"104","author":"S Luo","year":"2022","unstructured":"Luo S, He J, Huang S, Wang X, Su Y, Li Y, et al. Emodin targeting the colonic metabolism via PPAR\u03b3 alleviates UC by inhibiting facultative anaerobe. Phytomedicine. 2022;104: 154106.","journal-title":"Phytomedicine"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-024-01006-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-024-01006-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-024-01006-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T03:03:39Z","timestamp":1727319819000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmjournal.biomedcentral.com\/articles\/10.1186\/s13020-024-01006-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1006"],"URL":"https:\/\/doi.org\/10.1186\/s13020-024-01006-9","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]},"assertion":[{"value":"16 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed according to the Guidelines for Animal Experimentation of the Nanjing University of Chinese Medicine. The Animal Ethics Committee of Affiliated Hospital of Nanjing University of Chinese Medicine approved the animal experiments (Application Number: 2022DW-13-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}